Azathioprine showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
Azathioprine + infliximab showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with methotrexate (very low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawals due to adverse events compared with 5‐ASA or Sulfasalzine (low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).
It is very uncertain whether inulin and oligofructose 15 g changes withdrawals due to adverse events (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
It is very uncertain whether prebiotics changes withdrawals due to adverse events (4 weeks) compared with probiotics (very low certainty).
It is very uncertain whether prebiotics changes withdrawals due to adverse events (4 weeks) compared with synbiotics (very low certainty).
It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).
It is very uncertain whether mepolizumab 2.5 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).
It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 2.5 mg/kg (very low certainty).
Cromolyn sodium showed no clear difference in withdrawals due to adverse events at 8 weeks compared with placebo (low certainty).
It is very uncertain whether swallowed fluticasone changes withdrawals due to adverse events at 4 weeks compared with oral prednisone (very low certainty).
Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).
It is very uncertain whether esomeprazole changes withdrawals due to adverse events at 8 weeks compared with fluticasone (very low certainty).
It is very uncertain whether four‐food elimination and amino acid formula changes withdrawals due to adverse events at 6 weeks compared with four‐food elimination diet (very low certainty).
Infliximab 5 mg/kg and purine analogues showed no clear difference in withdrawals due to adverse events at week 26 compared with purine analogues alone (low certainty).
It is very uncertain whether leukotriene receptor antagonist changes withdrawals due to adverse events at 26 weeks compared with placebo (very low certainty).
The review found no eligible studies for this question.